Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 17 studies | 23% ± 6% | |
endothelial cell of lymphatic vessel | 9 studies | 25% ± 10% | |
adipocyte | 6 studies | 22% ± 3% | |
oligodendrocyte | 6 studies | 23% ± 8% | |
endothelial cell | 5 studies | 20% ± 5% | |
myofibroblast cell | 4 studies | 17% ± 2% | |
epithelial cell | 4 studies | 27% ± 13% | |
astrocyte | 4 studies | 29% ± 17% | |
adventitial cell | 3 studies | 30% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 24% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 3527.24 | 574 / 578 | 100% | 62.90 | 1152 / 1155 |
esophagus | 100% | 4124.44 | 1445 / 1445 | 99% | 63.25 | 181 / 183 |
ovary | 99% | 3024.86 | 179 / 180 | 99% | 60.06 | 426 / 430 |
intestine | 100% | 3079.26 | 966 / 966 | 98% | 32.56 | 517 / 527 |
skin | 99% | 2662.69 | 1792 / 1809 | 99% | 72.15 | 466 / 472 |
uterus | 100% | 4522.36 | 170 / 170 | 97% | 46.17 | 446 / 459 |
bladder | 100% | 2772.71 | 21 / 21 | 97% | 39.61 | 487 / 504 |
breast | 100% | 3471.96 | 459 / 459 | 96% | 41.63 | 1070 / 1118 |
thymus | 100% | 2983.16 | 652 / 653 | 91% | 23.13 | 553 / 605 |
pancreas | 89% | 2023.84 | 293 / 328 | 98% | 65.14 | 175 / 178 |
liver | 94% | 3333.37 | 212 / 226 | 93% | 40.09 | 376 / 406 |
prostate | 98% | 2678.91 | 240 / 245 | 88% | 22.37 | 441 / 502 |
stomach | 86% | 1912.19 | 309 / 359 | 99% | 37.03 | 283 / 286 |
kidney | 89% | 2031.92 | 79 / 89 | 87% | 38.30 | 781 / 901 |
brain | 45% | 522.48 | 1186 / 2642 | 98% | 35.22 | 689 / 705 |
adrenal gland | 67% | 831.89 | 172 / 258 | 48% | 10.74 | 110 / 230 |
adipose | 100% | 5638.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5944.75 | 1335 / 1335 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 19.42 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 47.46 | 79 / 80 |
tonsil | 0% | 0 | 0 / 0 | 98% | 63.48 | 44 / 45 |
muscle | 90% | 3216.70 | 724 / 803 | 0% | 0 | 0 / 0 |
heart | 82% | 1343.35 | 706 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 72% | 18.61 | 21 / 29 |
spleen | 26% | 200.30 | 62 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 4% | 43.15 | 39 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SPSB1 |
Protein name | SPRY domain-containing SOCS box protein 1 (SSB-1) SplA/ryanodine receptor domain and SOCS box containing 1 |
Synonyms | SSB1 |
Description | FUNCTION: Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins . Negatively regulates nitric oxide (NO) production and limits cellular toxicity in activated macrophages by mediating the ubiquitination and proteasomal degradation of NOS2 . Acts as a bridge which links NOS2 with the ECS E3 ubiquitin ligase complex components ELOC and CUL5 . . |
Accessions | A2A276 ENST00000377399.2 ENST00000328089.11 Q96BD6 ENST00000450402.1 ENST00000357898.3 |